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Abstract: Thioredoxin domain-containing 5 (TXNDC5) is a member of the protein 
disulfide isomerase family, acting as a chaperone of endoplasmic reticulum under not  
fully characterized conditions As a result, TXNDC5 interacts with many cell proteins, 
contributing to their proper folding and correct formation of disulfide bonds through its 
thioredoxin domains. Moreover, it can also work as an electron transfer reaction, recovering 
the functional isoform of other protein disulfide isomerases, replacing reduced glutathione 
in its role. Finally, it also acts as a cellular adapter, interacting with the N-terminal domain 
of adiponectin receptor. As can be inferred from all these functions, TXNDC5 plays  
an important role in cell physiology; therefore, dysregulation of its expression is associated 
with oxidative stress, cell ageing and a large range of pathologies such as arthritis, cancer, 
diabetes, neurodegenerative diseases, vitiligo and virus infections. Its implication in all 
these important diseases has made TXNDC5 a susceptible biomarker or even a potential 
pharmacological target. 
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1. Introduction 
The thioredoxin domain containing protein 5 (TXNDC5), also known as resident endoplasmic 
reticulum 46 (Erp46); protein disulfide isomerase family A, member 15 (PDI15); thioredoxin-related 
protein in the cell plasma (PC-TRP) or endo PDI; is a protein-disulfide isomerase. In fact, it is claimed 
to have thioredoxin (TRX) (Trx-like domains) that catalyze its thioredoxin activity and enable it to act 
as a chaperone in the endoplasmic reticulum (ER) [1]. There is evidence to suggest that TXNDC5 
expression is induced by hypoxia in endothelial cells [2] and endothelium of tumors [2]. TXNDC5 is 
upregulated in several cancers such as hepatocellular [3], breast, cervical, colon, esophageal, liver, 
lung, stomach and uterine carcinomas [4,5], in colorectal cancer [6], in non-small cell lung carcinoma [7] 
and renal tumor tissue [8]. Due to the anaerobic metabolism of cancer cells [4], it has been stated that 
their proliferation could be due to hypoxia and this would induce TXNDC5. This notion has been 
supported by studies in various diseases in which oxygen is limited, such as diabetes [9], arthritis [10–12], 
neurodegenerative diseases [13] and vitiligo [14]. However, hypoxia does not always induce TXNDC5 
upregulation. For example, in non-small cell lung carcinoma, hypoxia does not change TXNDC5 
expression [7], leaving an open horizon to better characterize its regulation. This wide spectrum of 
changes and controversies warrants further research in the future. 
Since TXNDC5 was discovered in 2003, a large amount of miscellaneous information has been 
published. To make advances in the field, the present report has adhered to systematic review  
guidelines [15]. All the data has been collected according to the criteria shown in Figure 1. The search 
in PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) using the keywords (TXNDC5 or Erp46) identified  
40 hits from November 1945 to July 2014. In addition, a search in electronic databases was carried out. 
The combined information of the two sources has been the basis of this review. 
2. TXNDC5 Gene 
TXNDC5 is a gene placed in the negative chain of Homo sapiens chromosome 6, particularly in the 
6p24.3 position, with a length of 29,565 bp. This gene contains 10 exons and 9 introns [1]. 
2.1. Orthologous Genes 
The TXNDC5 gene has also been found in other species, with orthologous genes in chimpanzee, 
mouse, rat, cow and dog, among others. Table 1 shows the orthologous genes most similar to genes 
found in Homo sapiens, accompanied by their taxonomic classification, and their names [1]. 
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Figure 1. Flow chart displaying the information collection process. Two different sources 
of data were used: Data from online bioinformatics databases and a search in PubMed. 
EndNote X1 (Thomson Reuters, New York, NY, USA). * Some references may appear in 
more than one section of the review. 
 
2.2. Paralogous Genes 
Groups of genes in different chromosomal locations in the same organism are paralogous. Their 
structure is similar, since they have evolved from the same ancestral gene. There are different 
TXNDC5 paralogs in humans, such as DNAJC10, PDIA6 or PDIA5. The first gene encodes for  
an endoplasmic reticulum (ER), chaperone, a part of a complex involved in recognition and 
degradation of misfolded proteins. This co-chaperone reduces incorrect disulfide bonds in misfolded 
glycoproteins. For its part, the PDIA6 gene encodes for a disulfide isomerase in the ER, responsible for 
formation, reduction and isomerization of disulfide bonds in proteins. Therefore it is thought to play  
a role in the folding of proteins with disulfide bonds. The last one, PDIA5, encodes member 5 of the 
protein disulfide isomerase family [1]. 
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Table 1. Orthologs of the human TXNDC5 gene. 
Organism 
Taxonomic 
Classification 
Gene Human Similarity 
Chimpanzee (Pan troglodytes) Mammalia TXNDC5 99.44 (n) 98.98 (a) 
Mouse (Mus musculus) Mammalia TXNDC5 86.81 (n) 89.57 (a) 
Rat (Rattus norvegicus) Mammalia TXNDC5 85.83 (n) 89.84 (a) 
Cow (Bos taurus) Mammalia TXNDC5 85.42 (n) 89.33 (a) 
Dog (Canis familiaris) Mammalia TXNDC5 85.91 (n) 87.76 (a) 
Opossum (Monodelphis domestica) Mammalia TXNDC5 78 (a) 
Platypus (Ornithorhynchus anatinus) Mammalia TXNDC5 69 (a) 
Chicken (Gallus gallus) Aves TXNDC5 74.53 (n) 74.53 (a) 
Lizard (Anolis carolinensis) Reptilia TXNDC5 66 (a) 
African clawed frog (Xenopus laevis) Amphibia BC045245.1 76.01 (n) 
Tropical clawed frog (Xenopus tropicalis) Amphibia MGC75894 76.45 (n) 
Zebrafish (Danio rerio) Actinopterygii Dr.25420 76.05 (n) 
Rainbow trout (Oncorhynchus mykiss) Actinopterygii BX307368.1 75.21 (n) 
Sea squirt (Ciona intestinalis) Ascidiacea Cin.2468 73.28 (n) 
Sea squirt (Ciona savignyi) Ascidiacea − 44 (a) 
Fruit fly (Drosophila melanogaster) Insecta Prtp 54.83 (n) 47.16 (a) 
Mosquito (Anopheles gambiae) Insecta AgaP_AGAP000044 53.96 (n) 43.51 (a) 
The percentage of similarity is shown followed by either (n) when the comparison was established using 
nucleic acid or (a) amino acid sequences, respectively. 
2.3. Gene Polymorphisms 
Single nucleotide polymorphisms (SNPs) represent the most common genetic variations in the 
human genome [16]. Supplementary Table S1 shows a large number of SNPs in the TXNDC5 gene.  
As can be seen, all SNPs associated with pathology are placed in non-coding regions of DNA (introns, 
5'-UTR and 3'-UTR), a fact that reveals the importance of these regions in gene expression and 
regulation of TXNDC5. 
2.4. TXNDC5 Transcripts 
The TXNDC5 gene encodes for six transcripts; while all are generated by alternative splicing, only 
two of them code for a protein (TXNDC5-001 and TXNDC5-003) [17]. TXNDC5-001 has 2964 bp 
distributed in 10 exons. It generates isoform 1 of TXNDC5, recognized as a canonical sequence, while 
TXNDC5-003 has 1301 bp distributed in 8 exons and generates a protein of 389 amino acids (isoform 2), 
which shares 75% identity with isoform 1; the two differ in the first 108 amino acids [17]. 
2.5. TXNDC5 Transcriptional Regulation 
As we mentioned above, the TXNDC5 gene has two transcriptional start sites, each one coding for 
one of the functional protein isoforms. Using the DECODE database, which has information based on 
experimental observations, ten transcription factors that could modulate TXNDC5 expression were 
predicted and are compiled in Table 2. The majority of them participate in general cell processes, 
Int. J. Mol. Sci. 2014, 15 23505 
 
 
modulating a wide range of the steps involved in gene transcription, and have ubiquitous expression [17,18]. 
Most of them are involved in misfolding protein processes, endoplasmic reticulum (ER) stress, 
hypoxia, differentiation, proliferation, apoptosis and cancer development [18]. 
Table 2. Transcription factors found to control TXNDC5 gene expression [19,20]. 
Transcription 
Factor 
Biology Process Tissue Expression 
HTF or HER-2 Growth factor receptor Epithelial tissue 
ATF6 
Leucine zipper in response to  
misfolded proteins via cAMP 
Ubiquitous expression 
XBP1 Plasma cell differentiation in response to ER stress Ubiquitous expression 
Pax6 Brain and eye morphogenesis 
Developing sensory organs, central 
nervous system and endocrine system 
ATF Differentiation, proliferation and apoptosis Ubiquitous expression 
cMyb Pro-oncogene Ubiquitous expression 
Max1 
Proliferation and apoptosis through  
H3 Lys-9 methyl-transferase complex 
Ubiquitous expression 
Arnt PAH pro-carcinogen activator in response to hypoxia Ubiquitous expression 
USF1 
Cell differentiation and proliferation Ubiquitous expression 
FCHL (Familiar combined hyperlipidemia) 
transcription factor 
Muscle and fat tissue 
2.6. TXNDC5 Post-Transcriptional Regulation 
TXNDC5 mRNA expression is also regulated by the conjoined gene (CG) MUTED-TXNDC5 [21]. 
MUTED is a gene related to lysosomes, melanosomes and high-density organelles biosynthesized  
in platelets. MUTED-TXNDC5 complex does not have any open reading frame for the gene MUTED  
sand only the 3'-UTR of the parental gene TXNDC5 is translated [21]. The presence of the CG  
MUTED-TXNDC5 may explain the lack of correlation between mRNA and protein levels in some tissues. 
3. TXNDC5 Protein 
TXNDC5 is a member of the disulfide isomerase (PDI) family [22], mainly expressed in liver and 
endothelial cells (where it is upregulated in hypoxia) [1,23]. Moreover, it has also been found in brain, 
spleen, lung, kidney, testis, and pancreas (particularly in β-cells), but it has not been detected in 
skeletal and heart muscle, or in the peripheral nervous system [1]. 
Regarding its cellular location, TXNDC5 seems to be mainly expressed in the ER [2]; nevertheless, 
it is also located in lysosomes, vacuoles, cytosol, Golgi, mitochondrion, plasma membrane and can 
even be exported to the extracellular medium [1]. 
3.1. Protein Structure 
TXNDC5 has three TRX (Trx-like domains), domains which contain a CXXC (two cysteines 
separated by two other amino acid residues) catalytic sequence, and, therefore, are believed to exert 
redox activity [24]. As represented in Figure 2, this protein also possesses a hydrophobic N-terminal 
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sequence and a C-terminal KDEL sequence that retains it in the ER. Furthermore, TXNDC5 has a second 
hydrophobic helix that can act as an additional transmembrane sequence or as a translocation  
signal [24]. A third feature of its structure comes from five central β-strands flanked by four α-helices. 
Conformational changes in this structure may play an important role in the protein function [25].  
As a non-globular protein, it can be found as a monomer and dimer in solution, with a molecular mass 
of 45 and 73 kDa, respectively [25]. 
Figure 2. Scheme showing TXNDC5 domains. The graphic shows the three Trx-like 
domains, placed between amino acids 14–95, 118–221 and 251–355 [26]. 
 
3.2. Post-Translational Modifications (PTMs) 
As a protein, TXNDC5 is susceptible to posttranslational modifications. As shown in Table 3, 
different web servers can predict where the PTMs can be placed most probably. With the exception of 
mannosylation, all other potential modifications are plausible. 
Table 3. Posttranslational modifications of TXNDC5 and participant amino acids. 
Modification Modified Amino Acids Prediction Server References 
Glycosylation 
Thr (174, 304, 306), Ser (308) DictyOGlyc [27] 
Thr (174, 299, 302, 304, 306), Ser (183, 308) NetOGlyc [28] 
No reports (*) NetNGlyc [29] 
Acetylation No reports (**) NetAcet [30] 
Mannosylation No reports (***) NetCGlyc [31] 
Phosphorylation 
Thr (138, 167, 174, 306, 335), Ser (62, 108, 125, 183, 
285, 364, 392, 409, 412, 419), Tyr (106, 151,192, 289) 
NetPhos [32] 
Thr (174, 304, 306), Ser (62, 108, 125, 129, 183, 197, 
238, 292, 308, 392, 409, 412, 419) 
Phosida [33,34] 
S-nitrosylation Cys (89, 92, 217, 220, 350, 353) GPS-SNO [35] 
Palmitoylation Cys (220) CSS-Palm [36] 
Sumoylation Lys (150, 241, 429) GPS-SUMO [37,38] 
Ubiquitination 
Lys (33,68,71,78,116,169,206,208,149,303, 
318,334,335, 337), Lys (41,68,71,78) 
BDM-PUB [39] 
CKSSAAP [40,41] 
* NetNGlyc reports no results, so there are no probable glycosylation sites in the N-terminal region of 
TXNDC5. Neither DictyOGlyc nor NetOGlyc report any glycosylation site in the N-terminal region;  
** NetAct found no Ala, Gly, Ser or Thr to be susceptible to acetylation; *** No results were found using 
NetCGlyc. Mannosylation is uncommon in mammal proteins, and mainly affects SNC (notwithstanding brain) 
and skeletal muscle, tissues in which TXNDC5 is not synthesized. All predictions were made using  
bio-informatics tools that checked homology of TXNDC5 protein domains with experimental databases for 
the PTMs. The sequence used to predict the PTMs of TXNDC5 was the canonical sequence of isoform 1. 
  
Int. J. Mol. Sci. 2014, 15 23507 
 
 
3.3. Protein Functions 
TXNDC5 catalyzes the rearrangement of disulfide bonds, due to its disulfide isomerase activity. 
First of all, it reduces the incorrect disulfide bonds formed in the newly folded proteins, and then 
catalyzes the oxidation of residues to arrange disulfide bonds in the native structure. This process is 
favored by the redox conditions of the ER [23,42]. For another thing, TXNDC5 has a chaperone 
activity, independent of its isomerase activity and in which TRX catalytic domains are not involved.  
It contributes to the oxidative folding of newly synthesized membrane proteins in the ER. Misfolded 
proteins are recognized by the quality control system of the ER and are marked for degradation via  
the proteasome [1]. TXNDC5 can also promote the correct protein folding by taking part in electron 
transfer to other oxidoreductases during the oxidation by Ero1-α-PDI, recovering the semi-reduced or 
reduced PDI isoform, taking over the role of GSH. However, Ero1-α showed lower affinity for 
TXNDC5 than other thioreductases (such as Erp44, Erp57 or Erp52) and TXNDC5 has higher oxygen 
consumption rates than the others [43,44]. On the other hand, the PRX4 protein can oxide a large range 
of PDIs, having special affinity for TXNDC5, binding the motif TRX, while Ero1α recognizes this 
protein by contact between a β-hairpin of Ero1α and the hydrophobic pocket of TXNDC5; thus, Ero1α 
has a lower efficiency than PRX4. As for peroxiredoxin 2, mutation analyses in TXNDC5 have shown 
that the complex stability of the latter involves disulfide bonds; so reducing its intramolecular disulfide 
bonds destabilizes the complex. In this way, protein interaction depends on the cell oxidation state. 
Other results of the differences in the binding mechanisms are the differing specificities of Ero1α and 
PRX4 toward PDIs, which allows each PDI to play a distinct and significant role during oxidative 
folding [45,46]. Several studies have shown that the conformation of the peptide rather than its 
sequence is important in the recognition and binding by TXNDC5. However, sequences usually show 
a recurrent motif of six residues that is constituted by one or more Phe or Tyr and other large 
hydrophobic amino acids, which can be interrupted by Lys, Arg or His. It is frequent to find Ser, Gly, 
Pro or Ala in the N-terminal domain [25]. 
Oxidative stress can disrupt the ER, which causes an abnormal protein folding, and cell apoptosis. 
As mentioned, TXNDC5 is involved in helping proteins to fold themselves correctly, and it protects cells 
from entering in apoptotic pathways. In this context, TXNDC5 seems to interact with isoform 2 of 
NADPH oxidase (Nox2) and this complex inhibits Nox2 activity. TXNDC5 also reduces RasC118, which 
limits Ras activation and plays an important role in NADPH oxidases and NOX function, modulating  
Ras expression in an indirect manner. These findings can be related to the antioxidative properties  
of statins. These agents induce proteins with antioxidative functions (TXNDC5), and downregulate 
oxidative proteins (Nox2). Thus, these findings give further support to the antioxidative function of 
TXNDC5 [47,48]. 
Finally, TXNDC5 has been proposed to act as a cellular adapter, interacting with the N-terminal 
domain of adiponectin receptor 1 (Adipo-R1); thus, enhancing TXNDC5 expression increases the 
interaction with Adipo-R1 and, indirectly, with AdipoR2 [49,50], an interaction observed in Chinese 
hamster ovary cells, but not confirmed in renal cell carcinoma [8]. Although immunohistochemistry 
showed co-localization of Adipo-R1 and ERp46 in membranes of the latter tissue, co-immunoprecipitation 
studies and crosslinking experiments did not show interactions between these two proteins and  
a bacterial adenylate cyclase-based two-hybrid assay using N-termini of Adipo-R1 and ERp46 
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revealed no evidence of protein interactions either. However, other transient interactions between 
Adipo-R1 and ERp46 cannot be ruled out [8]. Likewise, experiments did not evaluate additional 
proteins or cell conditions, such as oxidative and nitrosative stress, or hyperoxidation and S-nitrosylation  
of ERp46, which might modulate interactions of ERp46, and could affect the interaction between 
ERp46 and Adipo-R1. Finally, evidence suggests that ERp46’s N-terminus might not be the interacting 
site for Adipo-R1, and that catalytic thioredoxin domains of ERp46 constitute a potential peptide 
binding site for interactions [25]. Furthermore, an increase in TXNDC5 has been shown to down-regulate 
the serine threonine kinase, p38 MAPK. Likewise, a decrease in TXNDC5 levels causes an increase in 
MAPK stimulation, triggering adiponectin-induced phosphorylation in adipose tissue and synovial 
cells [49,50]. These findings indicate that the relationship between TXNDC5 and the adiponectin 
receptor 1 may be complex and variable according to tissue, and even within a given tissue, in terms of 
function, in order to achieve proper signal transduction of the adiponectin receptor. 
3.4. Protein Interactions 
TXNDC5, as a chaperone, interacts with a vast number of different proteins, having an important 
role in diverse cell processes. Although the methods used to discover these interactions (co-sedimentation,  
anti-tag coimmunoprecipitation, yeast-two-hybrid or enzymatic studies) do not enable us to unveil its 
biological role, this can be inferred by knowing the characteristics of proteins with which it interacts,  
as shown in Table 4. Thus, it may participate in histone modification, DNA transcription, mRNA 
splicing, cell cycle control, cell signaling, movement and transport, metabolism, and protein 
degradation. What is especially remarkable is its interaction with other chaperones, where TXNDC5 
can act as a co-chaperone, or even take part in electron transfer, as explained above. Along the same 
lines, the role of TXNDC5 in protein degradation, interacting with ubiquitinated and neddylated 
proteins, should be pointed out [51–53]. 
As is outlined below, some of these interactions can play an important role in certain diseases such 
as diabetes, neurodegenerative illnesses, cancer, vitiligo or arthritis. For instance, dysregulation in 
TXNDC5 may affect the cell cycle, through the cycling CDK5, histones or transcription factors such 
as ATF2 or ZNHIT2, being a possible cause of cancer. Loss of TXNDC5 function could promote APP 
misfolding and, consequently, play a key role in neurodegenerative diseases; moreover, its interaction 
with the zinc finger XNF706 could be involved in schizophrenia. TXNDC5 interactions with NENF, 
PPP1R2, ALDOC, LDH, or PGD could explain its implication in diabetes [51–53]. 
Beside all the protein interactions, TXNDC5 can also be associated with multiple compounds that 
cause oxidative stress, some of which are shown in Table 5 [54]. In fact, a docking assay (Figure 3A,B) 
carried out with the third TXNDC5 catalytic domain as a target and three ligands (cyclosporine A, 
diazoxide and paracetamol) revealed that there are three main zones to establish the interaction. These 
zones might be a part of the active or regulatory site. Nevertheless, further folding, activity and 
stability studies would be required to verify this hypothesis. 
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Table 4. Protein interactions of TXNDC5 and cell processes involved. 
Biological Process Proteins 
Histone deacetylation HdAFX, HDAC10, HDAC2 and RPD 
Transcription factors ATF, BZW1,GNAI3, ZNF207, ZNF706 and ZNHIT2 
Splicing PRPF4 
Cell cycle control CDK5 and VCP 
Cell signaling 
NENF (MAPK1/ERK2, MAPK3/ERK1 and ATK1/ATK phosphorylase), 
PPP1R2 (PP1 regulatory subunit (inhibitor)), Adipo-R1, AdipoR2, 
YWHANG and YWHAQ 
Cell transport YecS (amino acid and cys ABC transport) 
Cell movement CSE1L, DBN1 and WF1 
Ubiquitination YOD1, HMG-20, CUL3, UBC, UBE2V1, UBXN1 and NPLOC4 
Neddylation DCUN1D1 
Chaperones HSP90AA1, TBCB, TGM2, TRMT1 and UNC45A 
Carbohydrate metabolism ALDOC, LDH and PGD 
ATP ATP6V1A 
Amyloids APP 
Retrovirus ENV 
These interactions have been discovered by co-sedimentation, coimmunoprecipitation, enzymatic studies and 
yeast-two hybrid system [8,12,49–53]. 
Table 5. Interactions of TXNDC5 with different chemical compounds. 
Type of Agents Compounds 
Carcinogens 
2,3,7,8-Tetrachlorodibenzodioxine (herbicide),  
4'-Diaminodiphenylmethane, Benzopyrene 
Toxins Aflatoxin B1 
Immunosuppressor Cyclosporine A 
K+ channel activator Diazoside 
Adrenaline analogous Isoprenaline 
ROS Nitric oxide 
Oxocarbon Trimellitic anhydride 
PPARα Pirinixic acid 
Non-steroid anti-inflammatory Paracetamol 
Antibiotics Quinolones 
Anti-epilepsy drug Valproic acid 
Metals Zinc 
Vitamins Ascorbic acid 
Interactions among TXNDC5 and different organic and inorganic compounds, such as drugs and metabolites. 
All of them were experimentally discovered by different research groups [18,54–56]. 
4. TXNDC5 in Physiology and Pathology 
4.1. Diabetes 
Endocrine and exocrine pancreatic cells are known to have a high ER development, since this 
organelle is involved in folding, processing and exportation of enzymes and hormones. Several 
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conditions, such as oxidative stress, can disrupt ER function causing accumulation of misfolded 
proteins [57]. As TXNDC5 helps in correct insulin folding, when its concentration decreases in 
pancreatic islets, the amount of insulin is reduced, causing diabetes, so TXNDC5 has a central role in 
glucose toxicity. Moreover, low TXNDC5 levels increase C/EBP-homologous protein (CHOP) and 
peIF2a concentrations, causing ER stress and consequently increasing misfolded proteins [9,57]. 
TXNDC5 also protects pancreatic cells from palmitic acid-induced apoptosis by decreasing ER stress 
response, so it has potential to become a new pharmacological anti-diabetes target [9]. 
In addition, there is some TXNDC5 dysregulation in macrosomic placenta, a fact associated with  
a high probability of developing type 2 diabetes [1,58]. 
Figure 3. Current model of TXNDC5 interactions with different compounds. Panels (A)  
and (B) represent different angles of the docking assay using protein structure from Protein 
Data Bank [24]. First, many binding modes were generated by local and blind docking  
on the surface and in the cavities of the protein. Then, CHARMM (Chemistry at Harvard 
Macromolecules Mechanics) energies were estimated and most favorable energies were 
evaluated with FACTS (Fast Analytical Continuum Treatment of Solvation), clustered  
and visualized. Images show molecular coupling between TXNDC5 protein and the 
compounds cyclosporine A (blue), diazoside (red) and paracetamol (green). The interaction 
is mainly established within two domains of the protein involved in the action and its 
regulation [59,60]. 
 
4.2. TXNDC5 and Liver Diseases 
Non-alcoholic fatty liver causes an accumulation of fatty acids in the liver (steatosis) independently 
of alcohol abuse. In some patients it can develop into other diseases such as steatohepatitis, cirrhosis 
and hepatocellular carcinoma [61]. TXNDC5, which has been associated with regulation of ER stress,  
is influenced by hepatic fat and might play an important role in apolipoprotein B (APOB) control and 
steatosis development [61]. Moreover the cellular lipid metabolism is crucial for hepatitis C virus entry, 
replication, assembly and release, as lipid droplets are involved in viral particle production and release. 
Consequently, TXNDC5 expression may also influence HCV replication by its role in lipid droplets [62]. 
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Olive oil helps to reduce the accumulation of fatty acids thanks to the presence of squalene,  
an unsaponifiable lipid of this oil. It has been observed that high fatty acid levels, calcium deficiency 
and insulin resistance, may produce an ER homeostasis disruption, causing protein misfolding and 
generating oxidative stress. Squalene-supplemented diets in mouse models reduce fatty acid and 
cholesterol levels in liver while blood levels remain constant. In these models, it was also observed 
that the number and size of fatty droplets were both decreased. Moreover, TXNDC5 protein levels 
were found to be increased, while no changes in mRNA expression were detected. In conclusion, 
TXNDC5 and fatty acid levels are inversely related, even though this protein did not seem to 
contribute to reducing fatty droplet size. However, an increase in PDI-like chaperone expression,  
as with TXNDC5, may reduce misfolded protein and inclusion body accumulation [61]. 
4.3. Rheumatoid Arthritis 
Some gene polymorphisms (96) were found to be correlated with a high rheumatoid arthritis (RA) 
risk. These SNPs include five coding SNPs, 4 SNPs in the 3'-UTR, 35 and 53 tag SNPs or SNPs in intron 
near the 5' end. Only 25 of the 96 SNPs are related to the development of RA or ankylosing spondylitis 
(another type of arthritis). A total of 9 SNPs (rs9505298, rs41302895, rs1225936, rs1225938, rs372578, 
rs443861, rs408014, rs9392189 and rs2743992) showed substantial association with RA, while 16 SNPs 
(rs1044104, rs1225937, rs1225938, rs372578, rs89715, rs378963, rs1225944, rs1225947, rs1238994, 
rs369086, rs408014, rs368074, rs1225954, rs1225955, rs13209404 and rs3812162) had a significant 
association with ankylosing spondylitis. Moreover, rs443861 polymorphism is significantly associated 
with the onset of RA. In addition, rs443861 is considered to be good a risk marker for the disease [10,11]. 
Most of these polymorphisms are situated in or near a non-coding region of TXNDC5. 
TXNDC5 expression is increased in RA. Previous studies have found that TXNDC5 is increased 
under hypoxic conditions; so, in RA, a decrease in the oxygen supply causes TXNDC5 upregulation of 
expression, which can be observed in affected tissues, such as fibroblast-like cells, synovial fluids and 
blood [10]. 
As mentioned above, TXNDC5 may act as a cellular adapter interacting with Adipo-R1 and,  
in an indirect manner, with Adipo R2. Adiponectins are cytokine-like mediators produced in adipose 
tissue and synovial cells. They stimulate the release of chemokines, proinflammatory cytokines, 
prostaglandins, growth factors, and proteins of bone metabolism and of bone matrix remodeling. 
Therefore, activation of Adipo-R1 and AdipoR2 generates an increase in TNF-α, IL-1α, IL-1β, IL-17, 
which establishes a synergic relation in osteoclastogenesis and osteoclast function. This may explain 
the abnormal erosion found in RA [12,49,50]. Moreover, a rise in TXNDC5 levels causes a reduction 
in p38 mitogen-activated protein kinase phosphorylation. This fact contributes to inflammatory processes 
in response to TNF-α and IL-1 and plays a key role in lymphocyte migration to the injured tissues [49,50]. 
4.4. TXNDC5 and Cancer 
Several TXNDC5 polymorphisms have been associated with cancer. In this regard, two intronic 
SNP, rs1225944 and rs1225943, have been related to hepatocellular carcinoma in the recessive model 
and in the co-dominant 2, recessive and long-additive models, respectively, in the Korean male 
population [63]. They might affect mRNA splicing, generating a truncated protein. In addition, 
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homologues of TXNDC5 isoform 1, such as hemofiltrate CC-Chemokine-2 (Hcc-2), have been found 
to be upregulated in hepatocellular carcinoma [3]. Likewise, rs9505298, rs7771314, rs2815128, 
rs13210097 and rs9392182 polymorphisms could be involved in cervical, esophageal and liver carcinomas, 
since they have been found in tumor tissues with a high TXNDC5 expression, a circumstance that 
could be linked to an increase in tumor growth and invasive potential [4]. Moreover, TXNDC5 seems 
also to be involved in the development of gastric cancer [5]. In varioliform gastritis TXNDC5 is 
upregulated at the gastric mucosa, while the mucosa remains healthy at basal levels. Not surprisingly, 
varioliform gastritis can evolve into gastric cancer [64]. Further evidence of this TXNDC5 tumorigenic 
action was obtained when researchers showed that its inhibition by shRNA administration reduced 
tumor volume and weight [8] and decreased growth and invasive potential [4], a finding that indicates 
that TXNDC5 could be used as a biomarker and therapeutic target for cancer treatment. 
Tumor tissues are characterized by increased cell proliferation, angiogenesis and hypoxia.  
TXNDC5, as a protein induced by lack of oxygen, may be involved in these processes, acting as  
a tumor enhancer [4,64]. In fact, TXNDC5 mRNA and protein expression has been found to be 
increased in cervical, uterine, colon, stomach, prostate, liver and lung cancer [5,7], and the protein was 
significantly upregulated in colorectal adenoma and cancer [6] as compared with TXNDC5 levels in 
normal mucosa. In these tumor processes, the interaction between the N-terminal region of TXNDC5 
(amino acids 33 to 77) and Adipo-R1 (amino acids 1–70), which is induced by hypoxia, could play  
an important role as well. Specifically, in renal cell carcinoma, the ratio of Erp46/Adipo-R1 is 
increased in metastatic tissue compared with that from patients without metastasis [8]. Moreover, 
TXNDC5 expression is induced by ROS/RA stress and could be involved in pro-apoptotic pathways 
through the pro-oncogenic receptor NR4A1 in pancreatic tumor cells [65]. Likewise, TXNDC5 is 
required in the angiogenic function of endothelial cells. Erp46 interacts with TNF-α receptor 1 and 
controls TNF-α-induced endothelium angiogenic response. TNF-α enhances ERK1/2-mediated cell 
growth angiogenesis, raising AP-1 translation factor levels. TNF-α also controls cathepsin B 
expression and Ras activation. TXNDC5 reduces RasC118, which limits Ras activation. Although these 
two observations seem to be contradictory, recent studies show that RasC118-thiyl radical intermediate, 
rather than glutathionylated Ras, is the Ras species with the highest activity, and that glutathionylated 
Ras has an activity similar to that of native protein. Therefore, TXNDC5 could help to restore native 
Ras, allowing intermediate radical creation. Lowering TXNDC5 levels and levels of other PDIs would 
increase modified Ras accumulation, which could no longer be reduced and, consequently, could not 
be activated. Ras activation induces AP-1-dependent gene expression, contributing to endothelial cell 
angiogenesis in response to cytokines. Despite this fact, we can infer that an increase in TXNC5 
expression may contribute to the angiogenic response in cancer [48]. In addition, TXNDC5 can act as 
an enhancer for pro-oncogene MYC expression. MYC/IGH (insulin-like growth factor gene 1) 
rearrangements and up-expression contributes to tumor autonomy in multiple myeloma [66]. 
Also related to the Ras pathway, TXNDC5 seems to be implicated in cell aging. Current research 
validates the view that blood components exhibit protein changes related to cell aging. The levels of 
stress proteins, such as TXNDC5, are decreased in mononuclear and endothelial cells of older donor 
blood, compared with blood of younger individuals. These changes regulate signal transduction of the 
downstream Ras pathway, inducing Ras expression and increasing Ras protein levels, thus provoking 
Ras-induced senescence [67]. 
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4.5. TXNDC5 and Neurodegenerative Diseases 
Some TXNDC5 polymorphisms (rs13873) and BMP6-TXNDC5 polymorphisms (rs1225934, 
rs13873) are significantly related to schizophrenia due to a deficit in cluster 1, while cluster 2 is not 
modified [13]. 
S-nitrosylation is a nitric oxide-mediated, post-translational modification of cysteine residues with  
a physiological function in the cell. However, imbalance in S-nitrosylation rates reduces pro-survival 
proteins levels and is involved in neurodegenerative diseases. For instance, in neuroblastoma cells, 
TXNDC5 S-nitrosylation decreases, a circumstance that could modify multiple signal transduction 
pathways and compromise neuronal survival [68]. 
4.6. TXNDC5 and Vitiligo 
Seven polymorphisms have been associated with non-segmental vitiligo (NSV). Four SNPs are 
intronic (rs1225943, rs1225944, rs1225945 and rs1225958) and three of them are found in the tenth 
exon (rs1043784, rs7764128 and rs8643). NSV is a polygenic disease thought to involve TXNDC5 [14]. 
Vitiligo is a skin disease characterized by a depigmentation produced by a progressive loss of 
melanocytes. The causes remain unknown, but it has been attributed to autoimmune reactions, 
neurodegenerative causes, toxicity, genetics or oxidative stress; though by far, oxidative stress is the 
most widely accepted. Reactive oxygen species (ROS) may be responsible for melanocyte damage, 
and are also one of the causes of protein misfolding. According to this hypothetical setting, stressed 
cells would not die and would continue to produce misfolded proteins, which would represent  
a possible cause of vitiligo [14]. 
5. Conclusions 
The TXNDC5 gene is located on the minus strand of Homo sapiens chromosome 6. The fact that it 
has been preserved in different species may be indicative of the relevance of its function. Several 
paralogous genes codifying for chaperones have also been identified. The TXNDC5 gene codifies six 
transcripts by alternative splicing, but only two (TXNDC5-001 and TXNDC5-003) encode protein. The 
two isoforms differ in the first 108 amino acids, present only in the first of them. This gene also 
encodes a conjoined gene called MUTED-TXNDC5 that acts as a shRNA for TXNDC5. 
The protein TXNDC5, belonging to the disulfide isomerase family, is a thioredoxin peroxidase 
mainly expressed in liver and endothelial cells, although it can also be found in many other tissues.  
Its main cellular location is ER, but, it can also be located in other organelles and even in the 
extracellular medium. It catalyzes the rearrangement of disulfide bonds through its Trx-like domain. 
These domains also participate in electron transfer between TXNDC5 and Ero-1-α or peroxiredoxin 
proteins, conferring an oxidoreductase capacity on this protein. On the other hand, TXNDC5 also has  
a chaperone activity independent of the Trx-like domain, contributing to the folding of secreted 
proteins in the membrane. 
TXNDC5 may be related to several diseases. Some of its polymorphisms have been associated with 
the incidence of rheumatoid arthritis, vitiligo or neurodegenerative diseases. Furthermore, its modified 
expression in pancreatic cells may alter insulin folding and adiponectin response, which may be a new 
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etiology for diabetes. It is also involved in colon, liver, lung and stomach cancers, due to its role in 
angiogenesis and cell proliferation under hypoxia conditions. Its upregulation may act as a tumor 
enhancer, while its downregulation reduces tumor morbidity. According to this panorama, this protein 
is expected to play an important role in pathology in future years. 
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